AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches

06 Dec 2018

• By Emily Hayes

This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.

What a difference a few years made for acute myeloid leukemia R&D, as evidenced at the action-packed American Society of Hematology (ASH) annual meeting.

At the ASH meeting in December 2016, the treatment landscape was very limited, but the pipeline was plentiful, including a variety of drugs in late-stage development. (Also see "AML...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.